Search results for "Gallbladder Neoplasms"

showing 10 items of 10 documents

Intraductal aspiration: a promising new tissue-sampling technique for the diagnosis of suspected malignant biliary strictures

2012

Brushing is the most commonly used technique for biliary sampling at ERCP, despite its limited sensitivity. To evaluate intraductal aspiration (IDA) as a new combined endoscopic technique for cytodiagnosis, its cellular adequacy, diagnostic accuracy for cancer detection, feasibility, and safety. Prospective, observational study. Single tertiary referral center. IDA cellular adequacy, diagnostic accuracy for cancer detection, feasibility, and safety. From April 2009 to September 2010, 42 consecutive patients with suspected malignant biliary stricture underwent ERCP, with tissue sampling obtained with IDA. IDA included performance of standard brushing in all patients. After standard brushing,…

Suction (medicine)AdultMalemedicine.medical_specialtyCytodiagnosisConstriction PathologicCholangiocarcinomaPredictive Value of Testshemic and lymphatic diseasesBiopsymedicineHumansRadiology Nuclear Medicine and imagingSampling (medicine)Prospective StudiesProspective cohort studydiagnosis of suspected malignant biliary strictureIntraductal aspirationAgedAged 80 and overCholangiopancreatography Endoscopic RetrogradeCholestasisReceiver operating characteristicmedicine.diagnostic_testbusiness.industryBiopsy NeedleGastroenterologyTissue samplingMiddle AgedSurgeryCatheterBile Duct NeoplasmsPredictive value of testsFemaleGallbladder NeoplasmsRadiologyBile Ductsbusiness
researchProduct

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyur…

1996

BACKGROUND To date there is no established chemotherapeutic treatment for patients with unresectable locally advanced and/or metastatic carcinomas of the exocrine pancreas or the gallbladder. A multicenter Phase II trial has been performed by the Southern Italy Oncology Group with the aim of evaluating the clinical effectiveness and tolerability of weekly 5-fluorouracil (5-FU) in modulation with intravenous (i.v.) high dose levofolinic acid and oral hydroxyurea. METHODS A total of 70 patients fulfilling the standard eligibility for a Phase II study were enrolled in the trial. Forty patients had advanced pancreatic adenocarcinoma and 30 had advanced gallbladder carcinoma. The treatment sched…

OncologyMaleCancer Researchmedicine.medical_specialtyAntimetabolites AntineoplasticPancreatic diseaseAntidotesLeucovorinPhases of clinical researchAdministration OralAntineoplastic AgentsAdenocarcinomaGastroenterologyDrug Administration ScheduleMetastatic carcinomaInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansHydroxyureaInfusions IntravenousAgedbusiness.industryGallbladderCarcinomaRemission InductionLeukopeniaMiddle Agedmedicine.diseasePancreatic NeoplasmsSurvival Ratemedicine.anatomical_structureOncologyTolerabilityItalyInjections IntravenousDisease ProgressionAdenocarcinomaFemaleGallbladder NeoplasmsFluorouracilbusinessProgressive diseaseCancer
researchProduct

Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer

2019

AbstractGallbladder cancer (GBC) is a highly malignant tumor with poorly understood etiology. An insight into phenotypic features of this malignancy may add to the knowledge of its carcinogenesis and pave the way to new therapeutic approaches. We assessed the expression of female sex hormone receptors (ERα, ERβ, PR), connective tissue growth factor (CTGF) and HER2 in GBC, and adjacent normal tissue (NT), and determined their prognostic impact. Immunohistochemical (IHC) expression of all biomarkers was performed in formalin-fixed, paraffin-embedded specimens in 60 Caucasian GBC patients (51 women and 9 men). ERβ, cytoPR and CTGF expression were found in 89%, 27%, 91% of GBC, and in 63%, 87%,…

AdultMale0301 basic medicineReceptor ErbB-2Connective tissuelcsh:MedicinePathogenesismedicine.disease_causeArticleTumour biomarkersGastrointestinal cancer03 medical and health sciencesMedical research0302 clinical medicineBiomarkers TumorHumansMedicineGallbladder cancerReceptorlcsh:ScienceAgedAged 80 and overMultidisciplinarybusiness.industryGallbladderlcsh:RConnective Tissue Growth FactorGastroenterologyGallbladderMiddle AgedPrognosismedicine.diseaseCTGF030104 developmental biologymedicine.anatomical_structureOncologyRisk factorsHormone receptor030220 oncology & carcinogenesisCancer researchImmunohistochemistryFemaleGallbladder Neoplasmslcsh:QbusinessCarcinogenesisBiomarkersScientific Reports
researchProduct

"Pure" large cell neuroendocrine carcinoma of the gallbladder. Report of a case and review of the literature

2016

Primary Neuroendocrine Tumours (NETs) of the gallbladder are rare. Among all NETs of the gallbladder, large cell neuroendocrine carcinoma (LCNEC) is exceedingly rare. In most of the cases LCNECs are combined with other histological components. We reviewed clinical presentation and management of all patients with "pure" LCNEC from published literature since the first case was published in 2000, as well as one patient from our experience. Only 7 cases of "pure" LCNEC has been described in the last 15 years, our case is the eighth. The diagnosis of gallbladder NETs is rarely made preoperatively since the presentation generally consists of non-specific symptoms including upper abdominal pain, d…

medicine.medical_specialtyCarcinoma; Gallbladder; Large cell neuroendocrine carcinoma; Neuroendocrine carcinoma; Neuroendocrine tumours; SurgeryGallbladder Neuroendocrine Carcinomamedicine.medical_treatmentGallstonesAdenocarcinomaNeuroendocrine tumorsSettore MED/08 - Anatomia PatologicaDiagnosis Differential03 medical and health sciences0302 clinical medicineNeuroendocrine tumourmedicineCarcinomaHepatectomyHumansAgedIncidental Findingsbusiness.industryLarge cell neuroendocrine carcinomaGallbladderGeneral surgeryLiver NeoplasmsCarcinomaGallbladderGeneral MedicineGallstonesmedicine.diseaseCarcinoma NeuroendocrineNeuroendocrine TumorsSettore MED/18 - Chirurgia Generalemedicine.anatomical_structureCholecystectomy Laparoscopic030220 oncology & carcinogenesisNeuroendocrine carcinomaCarcinoma Large CellFemaleGallbladder Neoplasms030211 gastroenterology & hepatologySurgeryCholecystectomyRadiologyGallbladder NeoplasmDifferential diagnosisbusiness
researchProduct

Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers

2006

Background Biliary tract cancers are uncommon tumors with a poor prognosis and most patients present with invasive and inoperable disease at diagnosis. Chemotherapy represents a palliative treatment, with poor response rates and a median survival of less than 6 months. Oxaliplatin and gemcitabine have shown an interesting activity as single agents in this group of patients. Patients and methods We carried out a multicenter phase II study to evaluate the efficacy and safety of combined oxaliplatin and gemcitabine in locally advanced and metastatic biliary tract carcinoma. The schedule of chemotherapy included oxaliplatin 100 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8, every 21…

MaleOncologymedicine.medical_specialtyOrganoplatinum CompoundsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPhases of clinical researchAdenocarcinomaNeutropeniaDeoxycytidineDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansSurvival rateAgedChemotherapybusiness.industryCombination chemotherapyHematologyMiddle Agedmedicine.diseaseGemcitabineGemcitabineOxaliplatinOxaliplatinSurvival RateBile Duct NeoplasmsOncologyBiliary tractFemaleGallbladder Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia…

2006

Background The aim of the study was to test the clinical efficacy and toxicity profile of gemcitabine (GEM) in combination with cisplatin (CDDP) in a series of patients affected by unresectable and/or metastatic biliary tree carcinoma (BTC) previously untreated with chemotherapy. Patients and methods Overall 38 consecutive patients who satisfied eligibility criteria (10 with gall-bladder carcinoma and 28 with bile duct carcinoma) were included in this phase II study. Median age was 61 years with median PS 1. Treatment included GEM 1000 mg/m2/week as 30 min i.v. on days 1 and 8, and CDDP 75–80 mg/m2 on day 1 with adequate hydration protocol and forced diuresis. Treatment was repeated every 3…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchNeutropeniaDeoxycytidineGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansAgedChemotherapybusiness.industryHematologyMiddle Agedmedicine.diseaseGemcitabineGemcitabineSurgeryRegimenBile Duct NeoplasmsOncologyToxicityFemaleGallbladder NeoplasmsCisplatinbusinessProgressive diseasemedicine.drugAnnals of Oncology
researchProduct

Presence of white bile in malignant biliary obstruction is associated with poor prognosis: personal preliminary observations

2006

OBJECTIVE: The chemical composition and clinical significance of white bile in patients with malignant obstructive jaundice were evaluated in a prospective study. MATERIALS AND METHODS: 115 consecutive patients with inoperable malignant biliary obstruction underwent endoscopic placement of 10 Fr straight, plastic biliary stents, Amsterdam-type. Bile was aspirated during the endoscopic procedure and a blood sample was taken. Patients were divided into two groups: those with white bile and those with yellow bile. The groups were compared for decremental fall in bilirubin, cholangitis after stent insertion, and survival. RESULTS: Thirty-five patients (15 men, 20 women; mean age 54 years) under…

Malemedicine.medical_specialtyBilirubinmedicine.drug_classColordigestive systemGastroenterologyBile Acids and Saltschemistry.chemical_compoundInternal medicineBileHumansMedicineClinical significanceProspective StudiesProspective cohort studyAgedProportional Hazards ModelsCholestasisBile acidbusiness.industryBile ductBilirubinMiddle AgedJaundiceAlkaline PhosphatasePrognosisPancreatic NeoplasmsBiliary Tract Neoplasmsmedicine.anatomical_structurechemistryCardiothoracic surgeryFemaleGallbladder NeoplasmsStentsSurgerymedicine.symptombusinessAbdominal surgery
researchProduct

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO stud…

2014

Background: Since sorafenib has shown activity in different tumour types and gemcitabine regimens improved the outcome for biliary tract cancer (BTC) patients, we evaluated first-line gemcitabine plus sorafenib in a double-blind phase II study. Patients and methods: 102 unresectable or metastatic BTC patients with histologically proven adenocarcinoma of gallbladder or intrahepatic bile ducts, Eastern Cooperative Oncology Group (ECOG) 0–2 were randomised to gemcitabine (1000 mg/m2 once weekly, first 7-weeks + 1-week rest followed by once 3-weeks + 1-week rest) plus sorafenib (400 mg twice daily) or placebo. Treatment continued until progression or unacceptable toxicity. Tumour samples were p…

OncologyMaleCancer ResearchAdvanced biliary tract cancerPDGFRβPhases of clinical researchHif1αKaplan-Meier Estimateurologic and male genital diseasesGastroenterologyDeoxycytidineMetastasisAntineoplastic Combined Chemotherapy Protocolsheterocyclic compoundsProspective StudiesLymph nodeAged 80 and overVascular Endothelial Growth FactorsMiddle AgedSorafenibBTCfemale genital diseases and pregnancy complicationsmedicine.anatomical_structureBiliary Tract NeoplasmsTreatment OutcomeOncologyAdenocarcinomaFemaleGallbladder NeoplasmsHand-Foot Syndromemedicine.drugSorafenibAdultNiacinamidemedicine.medical_specialtyPlaceboDisease-Free SurvivalDrug Administration ScheduleDouble-Blind MethodInternal medicinemedicineBiomarkers TumorHumansddc:610neoplasmsAgedbusiness.industryGallbladderPhenylurea Compoundsmedicine.diseaseVascular Endothelial Growth Factor Receptor-2Gemcitabinedigestive system diseasesGemcitabineChemokine CXCL12VEGFR-3VEGFR-2Bile Ducts IntrahepaticBile Duct Neoplasmsc-kitQuality of LifebusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Expression of Cytokeratin 7 and 20 in Pathological Conditions of the Bile Tract

2003

Expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) helps to establish the origin of biliary and metastatic carcinomas. We investigated the expression of CK7 and CK20 in inflammatory, metaplastic and neoplastic conditions of the bile ducts, and evaluated possible relationships between the CK expression pattern and extrahepatic bile duct/gallbladder carcinomas (EBDCs) or intrahepatic bile duct carcinomas (IBDCs). We used immunohistochemistry for the investigation of 48 formalin-fixed, paraffin-embedded specimens grouped as: A) lithiasic or inflamed surgically resected extrahepatic bile ducts/gallbladders: all were CK7+/CK20+; B) percutaneous liver biopsies from patients with chronic …

medicine.medical_specialtyPathologyIntestinal metaplasia2734Intrahepatic bile ductsBile duct tumors; Cytokeratin 20 (CK20); Cytokeratin 7 (CK7); Intestinal metaplasia; Bile Duct Diseases; Bile Duct Neoplasms; Bile Ducts Extrahepatic; Bile Ducts Intrahepatic; Carcinoma; Cell Transformation Neoplastic; Gallbladder Diseases; Gallbladder Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Intermediate Filament Proteins; Keratin-20; Keratin-7; Keratins; 2734Bile Duct DiseasesGallbladder DiseasesKeratin-20Settore MED/08 - Anatomia PatologicaGastroenterologyIntermediate Filament ProteinPathology and Forensic MedicinePrimary sclerosing cholangitisCytokeratinPrimary biliary cirrhosisIntermediate Filament ProteinsBile Ducts ExtrahepaticInternal medicineBile duct tumormedicineHumansCytokeratin 7 (CK7)Bile Duct NeoplasmGallbladder NeoplasmBile ductbusiness.industryGene Expression ProfilingGallbladderKeratin 20CarcinomaGallbladder DiseaseKeratin-7Bile Duct DiseaseCell Biologymedicine.diseaseImmunohistochemistryBile Ducts IntrahepaticCell Transformation Neoplasticmedicine.anatomical_structureBile Duct NeoplasmsKeratinKeratin 7KeratinsGallbladder NeoplasmsbusinessCytokeratin 20 (CK20)HumanPathology - Research and Practice
researchProduct

Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control stud…

2007

OBJECTIVES: To identify risk factors of carcinoma of the extrahepatic biliary tract in men. METHODS: Newly diagnosed and histologically confirmed patients, 35-70 years old, were interviewed between 1995 and 1997 in Denmark, Sweden, France, Germany and Italy. Population controls were frequency-matched by age and region. Adjusted odds ratios and 95%-confidence intervals were estimated by logistic regression. RESULTS: The analysis included 153 patients and 1421 controls. The participation proportion was 71% for patients and 61% for controls. Gallstone disease was corroborated as a risk factor for extrahepatic biliary tract carcinoma in men (odds ratio 2.49; 95% confidence interval 1.32-4.70), …

MaleobesityEtiologyEpidemiologyMedizinGastroenterologyBody Mass Index0302 clinical medicineBile Ducts ExtrahepaticCholelithiasisRisk FactorsMedicineAlcohol consumption2. Zero hungerBiliary tract neoplasmeducation.field_of_studySmokingGastroenterologyCase-control studyMenGallstonesMiddle Agedmedical history3. Good healthBiliary tract carcinomaBiliary Tract Neoplasms030220 oncology & carcinogenesisMedical history030211 gastroenterology & hepatologyGallbladder NeoplasmsepidemiologyGallbladder carcinomaAdultmedicine.medical_specialtyAmpulla of Vateralcohol consumptioncase-control studyetiologyPopulationCommon Bile Duct Neoplasmsmensmoking03 medical and health sciencesInternal medicinesmoking.HumansObesityRisk factoreducationLife StyleAgedbiliary tract carcinomaHepatologybusiness.industryCase-control studyOdds ratiomedicine.diseaseConfidence interval[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCase-Control Studies[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiegallbladder carcinomabusinessBody mass index
researchProduct